Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

OCGN

$1.02-3.76%website ↗

Ocugen, Inc.

Market Cap
$461M
Sector
Materials
Industry
Biotechnology
Beta
1.93
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
24.0x
buying
Congress
—
recent trades
Short Volume
82%
W/W +41.4pp

Market & Alt Data

News
15
recent articles
Activist
—
none active
Analyst Consensus
Strong Buy
12 analysts
Velocity Score
23.98x
Current Rate (90d)
233.33/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
1
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-06-152026-06-17Johnson-Greene Treerita EssalimaChief Financial OfficerPurchase21.0K$1.23$26K521.0KView

Recent News

Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
SeekingAlpha · 2026-09-10
What's Happening With Ocugen Stock Thursday?
Benzinga · 2026-09-10
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5
Benzinga · 2026-09-10
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2026-09-09

Informational purposes only, not investment advice.

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 2026-09-09
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Yahoo · 2026-09-02
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Yahoo · 2026-09-01
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration
Benzinga · 2026-09-01
Ocugen to Participate in Upcoming September Investor and Industry Conferences
Yahoo · 2026-08-25
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Yahoo · 2026-08-16
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
Yahoo · 2026-08-13
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Yahoo Finance · 2026-08-07
Ocugen Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-07
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...
Yahoo Finance · 2026-08-06
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Yahoo Finance · 2026-07-11

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →